By Jenny Ruth
Friday 3rd June 2011
|Text too small?|
Fisher & Paykel Healthcare's annual result was slightly ahead of guidance but the company's guidance for the current year disappointed the market, says Guy Hallwright, an analyst at Forsyth Barr.
The company's $63.9 million result before a one-off $11.5 million tax charge compared with the company's $60 million to $63 million guidance.
It is forecasting net profit for the year ending March 2012 will be between $62 million and $76 million, assuming the New Zealand dollar is between 70 US cents and 80 cents.
"The upper end of the range was the market consensus pre-result and most forecasts will be revised down," Hallwright says.
Nevertheless, the company "has a positive growth outlook in both its businesses: solid underlying market growth in sleep apnoea along with expansion into new higher-priced segments, and expansion outside intensive care in respiratory and acute care," he says.
In the year ended March, obstructive sleep apnoea revenue in constant currency terms increased from 1% in the first half to 7% in the second half as the company rolled out its new Icon range.
"Fisher & Paykel Healthcare expects growth to be at least mid-teen percentages in full-year 2012, although we note this was also management's expectation for the second half but was not achieved," Hallwright says.
Valuation metrics, including multiple comparisons with competitor Resmed, "suggest limited share price upside."
No comments yet
NZ dollar rally may limit profit gains for Fisher and Paykel Healthcare, brokerage says
FISHER & PAYKEL HEALTHCARE ANNOUNCES NEW NASAL PILLOWS MASK AT INVESTOR DAY
Shares in Fisher and Paykel Healthcare third-best performer on NZX 50 after raising earnings forecast
Fisher and Paykel Healthcare raises 2014 earnings forecast on higher sales, margins
F and P Healthcare shares jump to highest in more than 2 years on profit outlook
F and P Healthcare beats 2013 guidance, forecasts boost in 2014 profit; shares gain to 2 1/2 year high
F and P Healthcare shares rise to two-year high as First NZ raises rating on better outlook
Fisher & Paykel Healthcare
F and P Healthcare lifts guidance as sales grow, margins widen; shares rally
F&P Healthcare 1H profit rises 18%, on record sales, wider margins